Antibodies and utilization thereof
View Patent ↗The anti-19P2 ligand monoclonal antibodies of the invention (in particular P2L-1Ca) have very high binding ability and can neutralize the arachidonic acid metabolite releasing activity of the 19P2 ligand. Therefore, they can be used, among others, as diagnostic, prophylactic and/or therapeutic agents for various diseases caused by some or other abnormality in the pituitary function modulating activity (e.g. prolactin secretion promoting activity), central nervous system modulating activity and pancreatic function modulating activity, among others, supposedly possessed by the 19P2 ligand. The immunoassay method using the monoclonal antibodies of the invention by the sandwich technique (in particular the sandwich technique using the monoclonal antibody and an antibody recognizing an intermediate portion of the 19P2 ligand) can assay the 19P2 ligand or a derivative thereof specifically and with high sensitivity. This assay method can be used in elucidating the physiological functions of the 19P2 ligand or a derivative thereof.
1. A monoclonal antibody that specifically binds to a peptide having an amino acid sequence of residues 12 to 24 of SEQ ID NO: 2.
2. The monoclonal antibody as claimed in claim 1 which is a mouse IgG.
3. A method of detecting 19P2 ligand in a test fluid which comprises using the monoclonal antibody of claim 1 in an assay, said assay comprising:
contacting the test fluid sample with said monoclonal antibody,
detecting any complexes form from the binding of said 19P2 ligand with said monoclonal antibody, and
relating the present or amount of said complexes to the present or amount of 19P2 ligand in said sample.
4. An isolated hybridoma cell producing the monoclonal antibody of claim 1 .
5. The monoclonal antibody of claim 1 , which specifically binds with a peptide having the amino acid sequence of SEQ ID NO: 11.
6. A method for detecting 19P2 ligand in a sample, comprising:
contacting said sample with the monoclonal antibody of claim 5 , and
detecting any complexes form from the binding of said 19P2 ligand to said monoclonal antibody, and
relating the present or amount of said complexes to the present or amount of 19P2 ligand in said sample.
7. The method of claim 6 , further comprising: assaying said sample wherein said 19P2 ligand is attached to a carrier.
8. The method of claim 6 wherein said monoclonal antibody is attached to a carrier.
9. The method of claim 6 wherein said monoclonal antibody is attached to a detectable signal or label.
10. The method of claim 6 which is a sandwich assay.
11. The method of claim 6 which is a competitive inhibition assay.
12. The method of claim 6 in which the monoclonal antibody is P2L-1Ta.
13. A method for detecting 19P2 ligand in a sample, comprising:
contacting said sample with the monoclonal antibody of claim 5 and a second antibody comprising an antibody which specifically binds to a peptide having the amino acid sequence of SEQ ID NO: 7, and
detecting any complexes form from the binding of the monoclonal antibody of claim 5 , said 19P2 ligand and said second antibody, and
relating the present or amount of said complexes to the present or amount of 19P2 ligand in said sample.
14. The monoclonal antibody of claim 1 , which specifically binds with a peptide having the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 5, or SEQ ID NO: 12.
15. The monoclonal antibody of claim 1 , which specifically binds with a peptide having the amino acid sequence of amino acid residues 12 to 24 or SEQ ID NO: 1, amino acid residues 12 to 24 of SEQ ID NO: 2, or amino acid residues 12 to 24 of SEQ ID NO: 3.
16. The monoclonal antibody of claim 1 , which specifically binds with a 19P2 ligand peptide, but which does not bind with a peptide having the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 6.
17. The monoclonal antibody of claim 1 , which is P2L-1Ta, as secreted by hybridoma NIBII 6300.
18. An isolated hybridoma cell line, having accession number NIBH 6300, said cell line producing the antibody P2L-1Ta.